Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23904374 | 0.83 | GRM1 (0.43) | GRM1FFAR3 | |
| SCHEMBL22279317 | 0.80 | GRM1 (0.50) | GRM1RAB9A | |
| SCHEMBL27041706 | 0.80 | GRM1 (0.61) | GRM1RAB9A | |
| SCHEMBL12308358 | 0.77 | GRM1 (0.37) | GRM1FFAR3 | |
| SCHEMBL20252858 | 0.77 | PKM (0.52) | GRM1 | |
| SCHEMBL15746432 | 0.75 | GRIN2D (0.52) | GRM1 | |
| SCHEMBL24806526 | 0.74 | GRM1 (0.54) | GRM1 | |
| SCHEMBL24907421 | 0.73 | THRB (0.39) | GRM1RAB9A | |
| SCHEMBL9142496 | 0.73 | GRM1 (0.50) | GRM1FFAR3 | |
| SCHEMBL1648486 | 0.73 | GRM1 (0.50) | GRM1FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4556469-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3740487-B1 | BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV | RECURIUM IP HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2024-06-06 | — | — | US | disclosed |
| CN-118084904-A | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-111801327-B | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813260-B1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-11590126-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2021007303-A1 | NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR | RECURIUM IP HOLDINGS, LLC (US) | 2021-01-14 | — | — | WO | disclosed |
| EP-3740487-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3737672-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3737681-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200338071-A1 | BENZAMIDE COMPOUNDS | ZENO MANAGEMENT, INC. | 2020-10-29 | — | — | US | disclosed |
| US-20200339605-A1 | BENZAMIDE COMPOUNDS | ZENO MANAGEMENT, INC. | 2020-10-29 | — | — | US | disclosed |
| CN-111801327-A | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2020-10-20 | — | — | CN | disclosed |
| CN-111801320-A | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2020-10-20 | — | — | CN | disclosed |
| CN-111788203-A | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | GRM1 4827/4885RAB9A 1631/4885FFAR3 4030/4885 |
| US-11813260-B1 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | GRM1 4827/4885RAB9A 1631/4885FFAR3 4030/4885 |
| US-11590126-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | GRM1 4827/4885RAB9A 1631/4885FFAR3 4030/4885 |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | GRM1 636/4885RAB9A 1622/4885FFAR3 3045/4885 |
| US-20200339605-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | GRM1 4827/4885RAB9A 1631/4885FFAR3 4030/4885 |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | GRM1 4827/4885RAB9A 1631/4885FFAR3 4030/4885 |
| US-20200338071-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | GRM1 4827/4885RAB9A 1631/4885FFAR3 4030/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | GRM1 3781/4885RAB9A 1761/4885FFAR3 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.